Thymulin

Thymulin, also known by its original French name Facteur Thymique Sérique (FTS, "serum thymic factor"), is a naturally occurring nonapeptide hormone produced exclusively by epithelial cells of the thymus gland. It was discovered and biochemically characterized by Jean-François Bach, Mireille Dardenne, Jean-Marie Pleau, and colleagues at the Institut Necker in Paris, published in a landmark 1977 paper in Nature (PMID 300146) — giving Thymulin one of the most credentialed discovery histories of any compound in this catalog, published in one of the highest-profile general-science journals rather than in institute-internal or narrowly specialized literature.

Chemically, Thymulin is a 9-residue peptide with the sequence pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (where pGlu denotes pyroglutamic acid, a cyclized form of glutamate at the N-terminus): molecular formula C33H54N12O15, molecular weight approximately 858.9 g/mol, CAS number 63958-90-7, PubChem CID 3085284. A defining, well-established feature of Thymulin is that it requires zinc to function: the zinc-free peptide (sometimes called apo-thymulin) is biologically inactive, while the zinc-bound complex (Zn-FTS) is the biologically active form, with zinc coordinated by the peptide's asparagine (position 9), serine (position 4), and N-terminal glutamate residues to form the correct three-dimensional conformation required for receptor engagement.

At Verified Peptides, we think this zinc-dependency is one of the most scientifically interesting and best-established features of any compound in our catalog, since it directly and mechanistically links a specific micronutrient (zinc) to a specific, well-characterized immune hormone's activity — a level of mechanistic clarity that most peptides in this catalog do not have.

At Verified Peptides, we think Thymulin has a meaningfully stronger and more independently verifiable evidence base than most other peptides built in this phase, and we want to walk through why. The foundational discovery paper (Bach et al., Nature, 1977, PMID 300146) is a landmark, high-impact-journal publication establishing Thymulin's biochemical identity, a different evidentiary tier from the institute-internal or vendor-sourced claims seen elsewhere in this catalog. A subsequent detailed review by two of the original discoverers, Dardenne and Pleau ("Interactions Between Zinc and Thymulin," 1994, PMID 18476235), further characterized the zinc-dependency relationship central to the compound's biology.

Thymulin's age-related decline and its connection to zinc status has been studied across multiple independent research groups over several decades, not confined to one originating laboratory the way several other Phase 4 compounds are — this is a genuinely international, multi-group research literature, consistent with Thymulin's status as a recognized endogenous immune hormone rather than a proprietary bioregulator product.

On the human side, we located a small, real clinical report: "An open trial of thymulin (FTS-Zn) in rheumatoid arthritis patients: sequential clinical and immunological follow-up" (Faure et al., Clinical and Experimental Rheumatology, 1987, PMID 3427844). We want to describe this accurately rather than overstate it: this is indexed as a brief communication/letter without an available abstract in the PubMed record, describing an open-label (non-blinded, non-placebo-controlled) trial design, which is a considerably lower evidentiary bar than a randomized controlled trial. We are citing it because it is a genuine, real, indexed human clinical report involving Thymulin directly — a distinction very few other compounds in this catalog can claim — while being clear that its open-label, letter-format design limits how much weight it should carry.

Beyond Thymulin itself, a substantial independent literature exists on zinc's broader immunological role in aging (zinc supplementation trials in elderly populations have reported reduced infection incidence and reduced inflammatory markers), which provides real, independently-established scientific context for why a zinc-dependent thymic hormone would be of ongoing research interest, even though this broader zinc literature is not itself Thymulin-specific evidence.

No FDA, EMA, or other Western regulatory body has approved Thymulin as a drug for any indication. At Verified Peptides, we sell research-grade Thymulin exclusively for laboratory research, and while its overall published research record is more substantial and independently distributed than most other compounds in this catalog, researchers should still treat the compound as investigational, without an established clinical therapeutic role.

Thymulin's zinc-dependency is one of the earliest and best-characterized examples of a specific trace mineral being required for a defined peptide hormone's biological activity, predating much of the now-extensive literature on zinc's broader immunological importance. This makes Thymulin something of a foundational case study in micronutrient-immune-hormone interaction, referenced well beyond its own specific compound literature in broader reviews of zinc and immune aging.

Thymulin is produced by thymic epithelial cells specifically, distinguishing its cellular origin from Thymosin Beta-4 (produced broadly across many tissue types) and from Khavinson's synthetic thymic dipeptide Vilon (not naturally produced in the body at all, but rather a designed fragment inspired by an earlier natural thymic extract, Thymalin). Researchers should keep these three thymus-associated compounds — Thymulin, Thymosin Beta-4, and Vilon — clearly distinct, since they differ in natural origin, chemical structure, and research history despite a shared general thymic/immune association.

The age-related decline in Thymulin bioactivity is one of the most robust, independently replicated findings associated with immune aging (immunosenescence) research generally, cited across numerous reviews of thymic involution independent of any single compound-marketing context — a genuinely different evidentiary situation from most other age-related-decline claims made about peptides in this catalog.

Because Thymulin's bioactivity depends on zinc binding, in vitro experimental protocols studying the peptide typically require careful attention to zinc availability in culture conditions; a Thymulin sample tested without adequate zinc supplementation in an assay system could appear inactive not because the peptide itself is degraded, but because the active zinc-bound conformation was never formed under those specific experimental conditions.

Researchers should also distinguish Thymulin from Thymopentin (TP-5), a separate synthetic pentapeptide corresponding to the active-site region of the larger protein thymopoietin — a different natural thymic hormone system entirely from Thymulin. Thymopentin has, notably, been approved as a pharmaceutical drug in some countries (including Italy and China) for immune-related indications, with its own separate human clinical trial history spanning HIV, rheumatoid arthritis, and primary immunodeficiency research. Thymulin and Thymopentin are frequently discussed in the same thymic-hormone literature and are sometimes confused due to their similar names and shared thymic origin, but they are structurally distinct peptides derived from entirely separate parent hormone systems (Thymulin from thymic epithelial cell secretion; Thymopentin from the thymopoietin protein), with independent research and regulatory histories that should not be conflated.

At Verified Peptides, we require independent third-party HPLC purity testing and mass spectrometry identity confirmation for every batch of research-grade Thymulin we offer, with a Certificate of Analysis (COA) available for each lot. As a well-characterized 9-residue peptide, Thymulin can be synthesized to high purity using standard solid-phase peptide synthesis methods.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Because Thymulin's biological activity depends specifically on zinc coordination, researchers should also consider zinc content and complexation when evaluating a given lot's likely bioactivity in an experimental system, not purity and identity of the peptide backbone alone.

Researchers should always request and review the specific COA for the lot they receive, confirming purity percentage and molecular identity before use in any experimental protocol. Given Thymulin's zinc-dependency, some research suppliers offer pre-complexed zinc-thymulin (Zn-FTS) preparations rather than the unbound apo-peptide; researchers should confirm exactly which form they are receiving, since the two are not interchangeable in bioactivity terms even though they share the same underlying peptide backbone.

Lyophilized Thymulin is stable when stored at -20°C, protected from light and moisture, and researchers can generally expect the unreconstituted peptide to maintain integrity over an extended period under these conditions. At Verified Peptides, we ship lyophilized peptide with appropriate cold-chain packaging to preserve stability in transit.

Once reconstituted with bacteriostatic water or another appropriate sterile diluent, Thymulin solution should be stored refrigerated at 2–8°C and used within the timeframe indicated on the product's documentation. As with other short peptides in this catalog, reconstituted solutions are generally less stable than the lyophilized form and more susceptible to degradation and microbial contamination with repeated freeze-thaw cycling.

Researchers working with Thymulin should also consider that its biological activity in downstream assays depends on zinc coordination, which is a separate consideration from the peptide's own physical/chemical storage stability — a fully intact, unstable-free peptide sample may still require zinc supplementation in the experimental system to reconstitute biological activity.